Overview

A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies

Phase:

Phase 1

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.